Skip to content

Azenta AZTA Sample Management Solutions and Multiomics — Total Assets

Other segment segments

Multiomics
$322.73M-28.4%

Similar metrics at other companies

Ashland logo
ASHLife Sciences — Total Assets
$1.46B-22.4%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Segment assets
$3.49B+15.6%
Bio-Rad Laboratories logo
BIOLife Science — Total Assets
$301.7M-2.1%
Fluor logo
FLRMission Solutions — Total Assets
$666M-15.1%
Thermo Fisher Scientific logo
TMOLaboratory Products and Biopharma Services — Segment assets
$6.92B+7.0%
Cardinal Health logo
CAHPharmaceutical and Specialty Solutions — Total Assets
$41.03B+14.8%

Other financials

Income statement

See full
Revenue$144.8M+1.0%
Gross profit$62.0M-1.2%
Operating income-$165.8M-811%
Net income-$160.8M-237%
EPS (diluted)-$3.49-236%

Balance sheet

See full
Cash & equivalents$125.2M
Total debt$55.7M
Total equity$1.6B-8.3%
Total assets$1.9B

Cash flow

See full
Operating cash flow$13.5M-6.2%
CapEx$7.4M-0.1%
Free cash flow$6.1M-12.7%

Valuation

See full
Market cap$1.1B-19.0%
Enterprise value$1.03B
P/S1.8×-0.3×

Profitability

See full
Gross margin40%-1.0pp
Operating margin-31.6%-59.7pp
Net margin-29.1%-80.7pp
FCF margin8.6%

Returns & leverage

See full
Return on equity-10.7%-22.4pp
Debt / equity
Current ratio2.8×

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's sample management solutions and multiomics — total assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Azenta's sample management solutions and multiomics — total assets?
Azenta (AZTA) reported sample management solutions and multiomics — total assets of $1.14B in Q1 2026.
What does sample management solutions and multiomics — total assets mean?
This metric represents the total carrying value of assets specifically allocated to the Sample Management Solutions and Multiomics business segment. It encompasses the infrastructure, inventory, and specialized equipment required to support cold-chain sample management and genomic services for life sciences clients. Monitoring these assets provides insight into the capital intensity and operational scale of the company's core service offerings within the drug development and clinical research markets.